Developer of high intensity focused ultrasound (HIFU) treatment of localized prostate cancer EDAP is currently conducting clinical research under an approved clinical trial combining the company's Ablatherm-HIFU device with chemotherapy using docetaxel at the Edouard Herriot Hospital in Lyon, France.
The study will serve as a primary treatment therapy program for men suffering from clinically localized but aggressive high-risk prostate cancer typically classified as stage T2c. The study, which began in late 2006, includes 30 men, of whom more than 10 have already been treated.
"This study aims to evaluate its use under an additional dedicated protocol for men in the T2c cancer stage where the tumors are known to be more aggressive, creating a higher risk of relapse if the patient is treated with only a localized therapy,” said Albert Gelet, MD of Edouard Herriot Hospital.
Under the French Ethical Committee’s protocol, doctors will administer a dose of docetaxel 30 minutes prior to a standard primary indication HIFU session lasting an average of two hours. The Ablatherm-HIFU ablates the prostate tissue according to conventional procedures and protocols.